Specializes in: Adults (18+ years), Geriatrics (55+ years)
Anal Cancer, Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Pancreatic Cancer, Radiation Oncology ...read more
Radiation therapy; gastrointestinal cancers; pancreatic cancer; colorectal cancer; stereotactic body radiation therapy; health services research; health economics; quality and safety research ...read more
Dr. Narang is an Assistant Professor in the Johns Hopkins Department of Radiation Oncology & Molecular Sciences. A former chief resident in the department, Dr. Narang now specializes in radiation treatment for gastrointestinal malignancies, including pancreatic cancer, colorectal cancer, hepatobiliary malignancies, and gastric cancer. Dr. Narang has an interest in expanding multi-disciplinary care for patients with gastrointestinal malignancies.
Dr. Narang has an interest in clinical trial development surrounding the use of radiation therapy for patients with gastrointestinal malignancies, in particular patients with pancreatic cancer. Dr. Narang is interested in optimizing the use of stereotactic body radiation therapy for various presentations of pancreatic cancer and other gastrointestinal malignancies. Dr. Narang is interested in exploring combinations of stereotactic radiotherapy with immunotherapy. Dr. Narang is also interested in health economics research to better delineate the value of care that we provide, along with developing relevant quality indicators for the care that we provide.
Pancreatic cancer; stereotactic body radiotherapy; immunotherapy; colorectal cancer; endorectal brachytherapy
Narang AK, Tran PT. Prostate cancer: case volume and improved outcomes across cancer care. Nat Rev Urol. 2016. Epub Feb 2. doi: 10.1038/nrurol.2016.15.
Narang AK, Chaichana KL, Weingart JD, Redmond KJ, Lim M, Olivi A, Quinones-Hinojosa A, Kleinberg LR. Impact of Progressive low-grade glioma: Assessment of prognostic importance of histologic reassessment and MRI findings. World Neurosurgery (in press)
Narang AK, Wright AA, Nicholas LH. Trends in advance care planning in patients with cancer: results from a national longitudinal survey. JAMA Oncol. 2015. epub Jul 9. doi: 10.1001/jamaoncol.2015.1976.
Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, Fuller CD, Pawlik TM, Miller RC, Czito BG, Tuli R, Crane CH, Ben-Josef E, Thomas CR, Herman JM. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Onc. 2015. epub Jul 30. doi: 10.1245/s10434-015-4685-y.
Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015 Jun;38(3):259-65.
Narang AK, Terezakis SA. Contemporary radiation in combined modality therapy for Hodgkin lymphoma. J Natl Compr Canc Netw. 2015 May;13(5):597-605.
Narang AK, Herman JM. The promise of modern radiotherapy in resected pancreatic adenocarcinoma: a response to Bekaii-Saab et al. Ann Surg Oncol. 2014 Apr;21(4):1064-6.
Walker AJ, Alcorn S, Narang AK, Nugent KM, Wild AT, Herman JM, Tran PT. Radiosensitizers in pancreatic cancer – preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer. 2013 Sep-Oct;37(5):301-12.
Alcorn S, Walker AJ, Gandhi N, Narang AK, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT. Molecularly targeted agents as radiosensitizers in cancer therapy – focus on prostate cancer. Int J Mol Sci. 2013 Jul;14(7):14800-32.
Narang AK, Lam E, Makary MA, Deweese TL, Pawlik TM, Pronovost PJ, Herman JM. Accuracy of marketing claims by providers of stereotactic radiation therapy. J Oncol Pract. 2013 Jan;9(1):57-62.
Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E. The quality of life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2013 Jan;85(1):e15-19.
Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, Tuli R, Laheru D, Wolfgang CL, Diaz LA Jr, Herman JM. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract Radiat Oncol. 2012;2:77-85.
Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, Hruban RH, Cameron JL, Schulick RD, Herman JM. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 2012 Apr;16(4):753-61.
Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011 Sep;6:126.
Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D, Eckhauser FE, Olson MT, Hruban RH, Miller RC, Andersen DK. Resectable pancreatic small cell carcinoma. Rare Tumors. 2011 Mar;3(1):e5.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.